Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTS85L)

• Drug Name: Capecitabine Drug Info
• Synonyms: Capecitabin; Capecitabina; Capecitabinum; Capecitibine; Capiibine; Caxeta; Xabine; Xeloda; Capecitabine [USAN]; R340;R-340; RG-340; Ro 09-1978; Xeloda (TN); Ro 09-1978/000; Ro-09-1978; Xeloda, Captabin, Capecitabine; Capecitabine (JAN/USAN/INN); Ro-09-1978/000; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecitabine (Fluoropyrimidine)

Indication

Disease Entry	ICD 11	Status	REF
Adenocarcinoma	2D40	Approved	[1]
Colon adenocarcinoma		Approved	[1]
Colorectal cancer	2B91.Z	Approved	[2]
Metastasis from malignant tumor of colon		Approved	[1]
Rectal adenocarcinoma	2B92	Approved	[1]
Breast cancer	2C60-2C65	Phase 3	[2]
Colon cancer	2B90.Z	Investigative	[1]
Gastric cancer	2B72	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 60953
  ChEBI ID: CHEMBL31348
  CAS Number: CAS 154361-50-9
  TTD Drug ID: DMTS85L
  VARIDT Drug ID: DR00380
  INTEDE Drug ID: DR0266
  ACDINA Drug ID: D00095

Molecule-Related Drug Atlas

Drug(s) Targeting Candida Thymidylate synthase (Candi TMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[8]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[9]
Pemetrexed	DMMX2E6	Central nervous system lymphoma	2B33.5	Approved	[10]
Trifluridine	DMG2YBD	Herpetic keratitis	1F00.10	Approved	[11]
Raltitrexed	DMT9K8G	Rectal adenocarcinoma	2B92	Approved	[12]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[13]
Flucytosine	DM13VTW	Cryptococcal meningitis		Approved	[14]
Nolatrexed	DMOF0CA	Solid tumour/cancer	2A00-2F9Z	Phase 3	[15]
Plevitrexed (R)-isomer	DMTL39C	Gastric adenocarcinoma	2B72	Phase 2	[16]
Plevitrexed	DM7Y60I	Gastric adenocarcinoma	2B72	Phase 2	[16]

Drug(s) Metabolized By Cytidine aminohydrolase (CDA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[17]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[18]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[19]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[20]

Drug(s) Metabolized By Thymidine phosphorylase (TYMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[21]
Trifluridine	DMG2YBD	Herpetic keratitis	1F00.10	Approved	[22]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[23]
Deoxythymidine	DMR90HY	Discovery agent	N.A.	Investigative	[24]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 2A (CDKN2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[25]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[26]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[27]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[28]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[29]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[30]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[31]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[32]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[33]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[34]

Drug(s) Affected By C-C motif chemokine 21 (CCL21)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[35]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Dihydroxyacetone	DMM1LG2	Sunburn	EJ40	Approved	[38]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[39]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[40]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[42]
USNIC ACID	DMGOURX	Discovery agent	N.A.	Investigative	[43]

Drug(s) Affected By CCN family member 1 (CCN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[44]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[45]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[46]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[45]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[50]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[51]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[52]

Drug(s) Affected By Aquaporin-8 (AQP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[53]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[55]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[56]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[42]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[57]

Drug(s) Affected By HLA class II histocompatibility antigen, DQ alpha 1 chain (HLA-DQA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[58]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[59]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[60]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[61]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[62]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[63]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[64]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[58]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[65]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[65]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[66]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[67]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[69]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[70]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[71]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[72]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[73]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[74]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[72]

Drug(s) Affected By B-lymphocyte antigen CD20 (MS4A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[75]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[42]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[76]

Drug(s) Affected By Nuclear receptor subfamily 4immunitygroup A member 1 (NR4A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[77]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[44]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[78]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[50]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[79]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[80]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[80]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[53]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[81]

Drug(s) Affected By 40-kDa huntingtin-associated protein (F8A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[83]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[84]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[85]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[86]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[87]

Drug(s) Affected By Chloride anion exchanger (SLC26A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[89]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[90]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[80]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[80]
Morniflumate	DM9UTDE	Otitis media	AA80-AB0Z	Approved	[91]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[93]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[92]

Drug(s) Affected By Nuclear receptor subfamily 4 group A member 2 (NR4A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[96]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[79]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[98]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[99]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[100]

Drug(s) Affected By Serine/threonine-protein kinase SIK1 (SIK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[102]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[53]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[102]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[103]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[102]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[102]

Drug(s) Affected By Hemoglobin subunit alpha (HBA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[104]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[105]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[93]
Flucloxacillin	DMNUWST	Bacterial infection	1A00-1C4Z	Approved	[107]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[109]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[84]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[64]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[110]

Drug(s) Affected By Fc receptor-like A (FCRLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[111]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[112]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[113]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[114]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[76]

Drug(s) Affected By Leucine-rich repeat-containing protein 15 (LRRC15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[60]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[64]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[116]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[117]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[118]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[42]

Drug(s) Affected By C-C motif chemokine 19 (CCL19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[36]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[119]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[64]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[120]
EUGENOL	DM7US1H	Discovery agent	N.A.	Patented	[121]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[76]
PHENCYCLIDINE	DMQBEYX	Discovery agent	N.A.	Investigative	[122]

Drug(s) Affected By E3 ubiquitin-protein ligase TRIM31 (TRIM31)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[123]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[124]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[125]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[126]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[127]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[128]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[42]

Drug(s) Affected By Interleukin-17 receptor B (IL17RB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[129]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[36]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[130]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[80]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[80]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[131]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]

Drug(s) Affected By Glycogen phosphorylase, brain form (PYGB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[132]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[83]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[117]

Drug(s) Affected By Calcium and integrin-binding protein 1 (CIB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[130]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[133]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[134]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[135]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[136]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[137]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[138]
paraquat	DMR8O3X	Discovery agent	N.A.	Investigative	[139]

Drug(s) Affected By 1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[132]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[140]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[134]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[141]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[142]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[143]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[144]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[83]

Drug(s) Affected By cAMP-dependent protein kinase catalytic subunit beta (PRKACB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[145]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[146]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[146]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[147]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[148]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[149]

Drug(s) Affected By Claudin-3 (CLDN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[150]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Sanguinarine	DMDINFS	Dental plaque	DA08.4	Approved	[151]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[147]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[152]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[84]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[153]

Drug(s) Affected By Replication protein A 70 kDa DNA-binding subunit (RPA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[25]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[154]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[155]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[156]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[53]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[54]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[157]

Drug(s) Affected By Protein flightless-1 homolog (FLII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[132]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[158]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[132]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[42]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[138]

Drug(s) Affected By Stress-induced-phosphoprotein 1 (STIP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[159]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[124]
Haloperidol	DM96SE0	Delirium		Approved	[157]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Tubocurarine	DMBZIVP	Anaesthesia	9A78.6	Approved	[160]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[157]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[157]
Mecamylamine	DMGQFYB	Essential hypertension	BA00	Approved	[160]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[161]

Drug(s) Affected By Ras-related protein R-Ras2 (RRAS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[162]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[140]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[163]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[164]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[125]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[165]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[143]

Drug(s) Affected By Cocaine esterase (CES2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[166]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[167]
Dextropropoxyphene	DM23HCX	Pain	MG30-MG3Z	Approved	[168]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[169]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[170]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[61]
Cantharidin	DMBP5N3	Molluscum contagiosum infection	1E76	Approved	[171]

Drug(s) Affected By Ras-related protein Rab-40B (RAB40B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[53]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[83]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[172]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[87]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[173]

Drug(s) Affected By Iron-sulfur clusters transporter ABCB7, mitochondrial (ABCB7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Gallium nitrate	DMF9O6B	Hypercalcaemia	5B91.0	Approved	[174]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[84]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[127]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[175]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[42]

Drug(s) Affected By Tyrosine-protein phosphatase non-receptor type 13 (PTPN13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[177]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[112]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[178]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[179]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[180]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[6]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[181]

Drug(s) Affected By ADP-ribosylation factor-like protein 4D (ARL4D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[134]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[142]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[182]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[183]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[184]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[64]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[185]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[117]

Drug(s) Affected By Double-strand break repair protein MRE11 (MRE11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[25]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[186]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[83]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[187]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[188]

Drug(s) Affected By Inorganic pyrophosphatase (PPA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[157]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[130]
Haloperidol	DM96SE0	Delirium		Approved	[157]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[157]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[157]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[143]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[144]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[83]

Drug(s) Affected By Polycystin-2 (PKD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[53]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Gentamicin	DMKINJO	Bacteremia	1A73	Approved	[189]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[190]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[64]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[6]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[117]

Drug(s) Affected By Protein S100-P (S100P)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[191]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[192]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[44]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[193]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[194]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[163]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[195]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[196]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[80]

Drug(s) Affected By Transcriptional activator Myb (MYB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[197]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[198]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[199]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[200]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[197]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[201]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[202]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[80]

Drug(s) Affected By 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (PLCE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[203]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[125]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[84]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[126]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[6]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[204]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[99]

Drug(s) Affected By Plakophilin-2 (PKP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[193]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[80]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[80]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[144]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[135]

Drug(s) Affected By Transcriptional enhancer factor TEF-1 (TEAD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[134]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[125]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[83]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[126]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[99]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[92]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[138]
Geldanamycin	DMS7TC5	Kidney cancer	2C90.0	Discontinued in Phase 2	[96]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[205]

Drug(s) Affected By Tyrosine-protein kinase receptor UFO (AXL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[132]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[206]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[46]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[206]
Plicamycin	DM7C8YV	Hypercalcaemia	5B91.0	Approved	[207]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[53]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[102]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[102]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[102]

Drug(s) Affected By Myelin regulatory factor (MYRF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[208]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[84]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[126]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[209]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[210]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[87]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[211]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[42]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[138]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[205]

Drug(s) Affected By Galectin-4 (LGALS4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[114]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[212]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[86]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[210]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[6]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[113]

Drug(s) Affected By Four and a half LIM domains protein 1 (FHL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[213]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[214]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[147]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[215]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[216]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[217]

Drug(s) Affected By Hepatoma-derived growth factor-related protein 3 (HDGFL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[130]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[128]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[87]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[99]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[113]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[218]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[131]
Lithium chloride	DMHYLQ2	Discovery agent	N.A.	Investigative	[219]

Drug(s) Affected By E3 ubiquitin-protein ligase TRIM15 (TRIM15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[83]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[126]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[64]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[220]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[42]

Drug(s) Affected By Dermatan-sulfate epimerase (DSE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[132]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[134]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[112]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[135]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[221]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[222]

Drug(s) Affected By Anterior gradient protein 2 homolog (AGR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[135]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[90]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[133]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[223]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[80]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[80]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]

Drug(s) Affected By Receptor tyrosine-protein kinase erbB-3 (ERBB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[224]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[225]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[203]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[105]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[226]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[227]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[228]

Drug(s) Affected By Aldo-keto reductase family 1 member B1 (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[229]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[230]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[54]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[231]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[112]
Benzoic Acid	DMKB9FI	Alopecia areata	ED70.2	Approved	[231]

Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[232]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[233]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[234]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[234]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[232]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[232]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[235]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[236]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[130]

Drug(s) Affected By 3-ketoacyl-CoA thiolase, peroxisomal (ACAA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[140]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[90]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[237]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[83]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[238]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[221]

Drug(s) Affected By Tissue alpha-L-fucosidase (FUCA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[145]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[50]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[76]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[93]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[112]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[83]

Drug(s) Affected By Epidermal growth factor receptor kinase substrate 8 (EPS8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Plicamycin	DM7C8YV	Hypercalcaemia	5B91.0	Approved	[239]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[53]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[106]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[157]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[143]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Thymidylate synthase (Candi TMP1)	TTU6BFZ	TYSY_CANAL	Inhibitor	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytidine aminohydrolase (CDA)	DEKEDRC	CDD_HUMAN	Substrate	[4]
Thymidine phosphorylase (TYMP)	DE4HCYL	TYPH_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2)	OT5I4Y9K	PLCB_HUMAN	Drug Response	[6]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (PLCE1)	OTJISZOX	PLCE1_HUMAN	Drug Response	[6]
3-ketoacyl-CoA thiolase, peroxisomal (ACAA1)	OTVKRET0	THIK_HUMAN	Drug Response	[6]
40-kDa huntingtin-associated protein (F8A1)	OTXTQ59R	HAP40_HUMAN	Gene/Protein Processing	[7]
ADP-ribosylation factor-like protein 4D (ARL4D)	OTG5I3KU	ARL4D_HUMAN	Drug Response	[6]
Aldo-keto reductase family 1 member B1 (AKR1B1)	OTRX72TH	ALDR_HUMAN	Drug Response	[6]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Drug Response	[6]
Anterior gradient protein 2 homolog (AGR2)	OTRRZT7W	AGR2_HUMAN	Drug Response	[6]
Aquaporin-8 (AQP8)	OT99JKME	AQP8_HUMAN	Gene/Protein Processing	[7]
B-lymphocyte antigen CD20 (MS4A1)	OTZTVUBX	CD20_HUMAN	Gene/Protein Processing	[7]

References

• [1] Capecitabine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6799).
• [3] UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
• [4] Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805.
• [5] Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct;1(12):1139-45.
• [6] Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.
• [7] Gene expression responses reflecting 5-FU-induced toxicity: Comparison between patient colon tissue and 3D human colon organoids. Toxicol Lett. 2022 Dec 1;371:17-24. doi: 10.1016/j.toxlet.2022.09.013. Epub 2022 Sep 29.
• [8] The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
• [9] Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
• [10] Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
• [11] Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
• [12] DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
• [13] Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
• [14] Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
• [15] A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
• [16] Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
• [17] Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74.
• [18] Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44.
• [19] A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep;22(9):1680-4.
• [20] Tracking decitabine incorporation into malignant myeloid cell DNA in vitro and in vivo by LC-MS/MS with enzymatic digestion. Sci Rep. 2019 Mar 14;9(1):4558.
• [21] 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65.
• [22] Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct;26(8):794-9.
• [23] Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm. 2008 Sep-Oct;5(5):717-27.
• [24] Thymidine catabolism as a metabolic strategy for cancer survival. Cell Rep. 2017 May 16;19(7):1313-1321.
• [25] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [26] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [27] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [28] A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
• [29] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [30] Expression of the helix-loop-helix protein inhibitor of DNA binding-1 (ID-1) is activated by all-trans retinoic acid in normal human keratinocytes. Toxicol Appl Pharmacol. 2006 Aug 1;214(3):219-29. doi: 10.1016/j.taap.2005.12.015. Epub 2006 Feb 21.
• [31] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [32] [Re-expression of p16 gene in myeloma cell line U266 by arsenic trioxide]. Ai Zheng. 2004 Jun;23(6):626-30.
• [33] p16 loss facilitate hydroquinone-induced malignant transformation of TK6 cells through promoting cell proliferation and accelerating the cell cycle progression. Environ Toxicol. 2021 Aug;36(8):1591-1599. doi: 10.1002/tox.23155. Epub 2021 May 1.
• [34] Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol. 2008;47(6):1062-70.
• [35] Chronic senescent human mesenchymal stem cells as possible contributor to the wound healing disorder after exposure to the alkylating agent sulfur mustard. Arch Toxicol. 2021 Feb;95(2):727-747. doi: 10.1007/s00204-020-02946-5. Epub 2021 Jan 25.
• [36] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [37] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [38] The sunless tanning agent dihydroxyacetone induces stress response gene expression and signaling in cultured human keratinocytes and reconstructed epidermis. Redox Biol. 2020 Sep;36:101594. doi: 10.1016/j.redox.2020.101594. Epub 2020 May 29.
• [39] Pattern of expression of apoptosis and inflammatory genes in humans exposed to arsenic and/or fluoride. Sci Total Environ. 2010 Jan 15;408(4):760-7. doi: 10.1016/j.scitotenv.2009.11.016. Epub 2009 Dec 4.
• [40] Effect of ovarian steroids on gene expression profile in human uterine microvascular endothelial cells. Fertil Steril. 2009 Aug;92(2):709-21.
• [41] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [42] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [43] Effects of usnic acid exposure on human hepatoblastoma HepG2 cells in culture. J Appl Toxicol. 2012 Sep;32(9):722-30.
• [44] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [45] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [46] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [47] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [48] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [49] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [50] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [51] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [52] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [53] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [54] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [55] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [56] Mitochondrial aquaporin-8 knockdown in human hepatoma HepG2 cells causes ROS-induced mitochondrial depolarization and loss of viability. Toxicol Appl Pharmacol. 2012 Oct 15;264(2):246-54. doi: 10.1016/j.taap.2012.08.005. Epub 2012 Aug 15.
• [57] Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environ Res. 2019 Jun;173:124-134. doi: 10.1016/j.envres.2019.03.035. Epub 2019 Mar 18.
• [58] A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010 Aug;42(8):711-4. doi: 10.1038/ng.632. Epub 2010 Jul 18.
• [59] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [60] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [61] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [62] Glucocorticoid regulation of human eosinophil gene expression. J Steroid Biochem Mol Biol. 2003 Mar;84(4):441-52. doi: 10.1016/s0960-0760(03)00065-7.
• [63] Transcriptomics and methylomics of CD4-positive T cells in arsenic-exposed women. Arch Toxicol. 2017 May;91(5):2067-2078. doi: 10.1007/s00204-016-1879-4. Epub 2016 Nov 12.
• [64] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [65] HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014 Oct;46(10):1131-4. doi: 10.1038/ng.3093. Epub 2014 Sep 14.
• [66] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [67] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [68] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [69] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [70] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [71] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [72] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [73] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [74] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [75] Gene-expression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4. Exp Hematol. 2007 Jan;35(1):84-95.
• [76] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [77] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [78] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [79] Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010 Jun 2;9:56. doi: 10.1186/1476-511X-9-56.
• [80] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [81] Febuxostat Increases Ventricular Arrhythmogenesis Through Calcium Handling Dysregulation in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Toxicol Sci. 2022 Sep 24;189(2):216-224. doi: 10.1093/toxsci/kfac073.
• [82] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [83] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [84] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [85] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [86] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [87] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [88] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [89] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [90] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [91] Acute regulation of the SLC26A3 congenital chloride diarrhoea anion exchanger (DRA) expressed in Xenopus oocytes. J Physiol. 2003 May 15;549(Pt 1):3-19. doi: 10.1113/jphysiol.2003.039818. Epub 2003 Mar 21.
• [92] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [93] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [94] Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis. Mol Immunol. 2009 Oct;46(16):3345-57. doi: 10.1016/j.molimm.2009.07.019. Epub 2009 Sep 3.
• [95] Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
• [96] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [97] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [98] Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound. Toxicol In Vitro. 2021 Jun;73:105112. doi: 10.1016/j.tiv.2021.105112. Epub 2021 Feb 22.
• [99] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [100] Identification of cornifelin and early growth response-1 gene as novel biomarkers for in vitro eye irritation using a 3D reconstructed human cornea model MCTT HCE?. Arch Toxicol. 2015 Sep;89(9):1589-98. doi: 10.1007/s00204-014-1390-8. Epub 2014 Nov 7.
• [101] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [102] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [103] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [104] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [105] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [106] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [107] Identification of flucloxacillin-modified hepatocellular proteins: implications in flucloxacillin-induced liver injury. Toxicol Sci. 2023 Mar 20;192(1):106-116. doi: 10.1093/toxsci/kfad015.
• [108] Real-time monitoring of cisplatin-induced cell death. PLoS One. 2011;6(5):e19714. doi: 10.1371/journal.pone.0019714. Epub 2011 May 16.
• [109] Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009 Apr;11(4):361-71. doi: 10.1111/j.1463-1326.2008.00970.x. Epub 2009 Jan 22.
• [110] Progesterone regulation of implantation-related genes: new insights into the role of oestrogen. Cell Mol Life Sci. 2007 Apr;64(7-8):1009-32.
• [111] Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
• [112] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [113] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [114] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [115] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [116] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [117] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [118] Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol Cell Proteomics. 2011 Jan;10(1):M110.002170.
• [119] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [120] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [121] Chemicals with weak skin sensitizing properties can be identified using low-density microarrays on immature dendritic cells. Toxicol Lett. 2007 Nov 1;174(1-3):98-109. doi: 10.1016/j.toxlet.2007.08.015. Epub 2007 Sep 5.
• [122] Differential response of Mono Mac 6, BEAS-2B, and Jurkat cells to indoor dust. Environ Health Perspect. 2007 Sep;115(9):1325-32.
• [123] Agonist and antagonist of retinoic acid receptors cause similar changes in gene expression and induce senescence-like growth arrest in MCF-7 breast carcinoma cells. Cancer Res. 2006 Sep 1;66(17):8749-61.
• [124] Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
• [125] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [126] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [127] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [128] Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
• [129] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [130] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [131] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [132] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [133] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [134] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [135] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [136] Exploring pradimicin-IRD antineoplastic mechanisms and related DNA repair pathways. Chem Biol Interact. 2023 Feb 1;371:110342. doi: 10.1016/j.cbi.2023.110342. Epub 2023 Jan 10.
• [137] Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
• [138] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [139] An in vitro strategy using multiple human induced pluripotent stem cell-derived models to assess the toxicity of chemicals: A case study on paraquat. Toxicol In Vitro. 2022 Jun;81:105333. doi: 10.1016/j.tiv.2022.105333. Epub 2022 Feb 16.
• [140] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [141] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [142] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [143] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [144] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [145] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [146] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [147] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [148] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
• [149] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [150] Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm Bowel Dis. 2019 May 4;25(6):1006-1018. doi: 10.1093/ibd/izz017.
• [151] Anti-invasive activity of sanguinarine through modulation of tight junctions and matrix metalloproteinase activities in MDA-MB-231 human breast carcinoma cells. Chem Biol Interact. 2009 May 15;179(2-3):185-91. doi: 10.1016/j.cbi.2008.11.009. Epub 2008 Nov 21.
• [152] Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 2006 Jan;97(1):64-71.
• [153] Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
• [154] Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
• [155] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [156] XPC is essential for nucleotide excision repair of zidovudine-induced DNA damage in human hepatoma cells. Toxicol Appl Pharmacol. 2011 Mar 1;251(2):155-62. doi: 10.1016/j.taap.2010.12.009. Epub 2010 Dec 28.
• [157] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [158] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [159] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [160] Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
• [161] Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
• [162] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [163] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [164] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [165] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [166] Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos. 2000 Feb;28(2):186-91.
• [167] Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. Cancer Biol Ther. 2006 Nov;5(11):1450-6.
• [168] Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther. 1999 Jul;290(1):314-8.
• [169] Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chem Biol Interact. 2013 Mar 25;203(1):226-30.
• [170] Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci. 2007 Jan;95(1):13-22.
• [171] Hepatoxicity mechanism of cantharidin-induced liver LO2 cells by LC-MS metabolomics combined traditional approaches. Toxicol Lett. 2020 Oct 15;333:49-61. doi: 10.1016/j.toxlet.2020.07.024. Epub 2020 Jul 26.
• [172] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [173] New insights into BaP-induced toxicity: role of major metabolites in transcriptomics and contribution to hepatocarcinogenesis. Arch Toxicol. 2016 Jun;90(6):1449-58.
• [174] Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radic Biol Med. 2008 Sep 15;45(6):763-72.
• [175] Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
• [176] Role of transporter genes in cisplatin resistance. In Vivo. 2008 May-Jun;22(3):279-83.
• [177] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [178] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [179] Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 Oct;12(7):e55-67.
• [180] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [181] Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther. 2005 Feb;4(2):233-41.
• [182] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [183] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [184] Gene induction and apoptosis in human hepatocellular carci-noma cells SMMC-7721 exposed to 5-aza-2'-deoxycytidine. Chin Med J (Engl). 2007 Sep 20;120(18):1626-31.
• [185] Research resource: STR DNA profile and gene expression comparisons of human BG-1 cells and a BG-1/MCF-7 clonal variant. Mol Endocrinol. 2014 Dec;28(12):2072-81.
• [186] Bisbenzamidine derivative, pentamidine represses DNA damage response through inhibition of histone H2A acetylation. Mol Cancer. 2010 Feb 9;9:34. doi: 10.1186/1476-4598-9-34.
• [187] DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008 Jan;28(2):752-71. doi: 10.1128/MCB.01799-07. Epub 2007 Nov 8.
• [188] Deletion of NAD(P)H:quinone oxidoreductase 1 represses Mre11-Rad50-Nbs1 complex protein expression in cisplatin-induced nephrotoxicity. Toxicol Lett. 2016 Jan 22;243:22-30.
• [189] Deficiency of polycystin-2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells. FASEB J. 2004 May;18(7):884-6. doi: 10.1096/fj.03-0687fje. Epub 2004 Mar 4.
• [190] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• [191] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [192] S100P is selectively upregulated in tumor cell lines challenged with DNA cross-linking agents. Leuk Res. 2005 Oct;29(10):1181-90. doi: 10.1016/j.leukres.2005.03.012.
• [193] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [194] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [195] Using a customized DNA microarray for expression profiling of the estrogen-responsive genes to evaluate estrogen activity among natural estrogens and industrial chemicals. Environ Health Perspect. 2004 May;112(7):773-81. doi: 10.1289/ehp.6753.
• [196] Extracellular ATP drives breast cancer cell migration and metastasis via S100A4 production by cancer cells and fibroblasts. Cancer Lett. 2018 Aug 28;430:1-10. doi: 10.1016/j.canlet.2018.04.043. Epub 2018 May 5.
• [197] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [198] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [199] Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells. J Pharmacol Exp Ther. 2003 Jun;305(3):932-42. doi: 10.1124/jpet.103.049098. Epub 2003 Mar 20.
• [200] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [201] Hypomethylation mediated by decreased DNMTs involves in the activation of proto-oncogene MPL in TK6 cells treated with hydroquinone. Toxicol Lett. 2012 Mar 25;209(3):239-45. doi: 10.1016/j.toxlet.2011.12.020. Epub 2012 Jan 8.
• [202] Thalidomide alters c-MYB and PIM-1 signaling in K-562 cells. Pharmacol Res. 2006 Aug;54(2):91-6. doi: 10.1016/j.phrs.2006.02.010. Epub 2006 Mar 8.
• [203] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [204] Epigallocatechin-3-gallate (EGCG) protects against chromate-induced toxicity in vitro. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):166-75.
• [205] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [206] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [207] The human receptor tyrosine kinase Axl gene--promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep. 2008 Jun;28(3):161-76. doi: 10.1042/BSR20080046.
• [208] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [209] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [210] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [211] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [212] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [213] An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
• [214] Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
• [215] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [216] Isoproterenol effects evaluated in heart slices of human and rat in comparison to rat heart in vivo. Toxicol Appl Pharmacol. 2014 Jan 15;274(2):302-12.
• [217] Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
• [218] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [219] Early gene response in lithium chloride induced apoptosis. Apoptosis. 2005 Jan;10(1):75-90. doi: 10.1007/s10495-005-6063-x.
• [220] The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics. 2010 Aug 13;3:37. doi: 10.1186/1755-8794-3-37.
• [221] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [222] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [223] Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells. Anticancer Res. 2006 Sep-Oct;26(5A):3205-15.
• [224] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [225] Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.
• [226] Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
• [227] The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem. 2004 May;260(1-2):129-35. doi: 10.1023/b:mcbi.0000026063.96267.98.
• [228] Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor. Cancer Prev Res (Phila). 2010 Apr;3(4):560-72. doi: 10.1158/1940-6207.CAPR-09-0159. Epub 2010 Mar 23.
• [229] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [230] Posttranslational glutathiolation of aldose reductase (AKR1B1): a possible mechanism of protein recovery from S-nitrosylation. Chem Biol Interact. 2009 Mar 16;178(1-3):250-8. doi: 10.1016/j.cbi.2008.11.007. Epub 2008 Nov 18.
• [231] Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
• [232] Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
• [233] Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
• [234] Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
• [235] In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
• [236] AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
• [237] Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.
• [238] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [239] Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. Chem Biol Interact. 2010 Jan 5;183(1):181-6. doi: 10.1016/j.cbi.2009.09.018.